DISTINCT SYNDROME of calcitriol (1,25-dihy-A droxyvitamin D,)-mediated hypercalcemia is seen in patients with Hodgkin's disease and non-Hodgkin's lymphomas (NHL). In addition to hypercalcemia, this syndrome is characterized by intestinal hyperabsorption of calcium, normal serum phosphate levels, the absence of renal phosphate wasting, and increased renal excretion of calcium. Other characteristic features include normal or suppressed serum parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) concentrations and normal nephrogenous cyclic adenosine monophosphate production.
cium, normal serum phosphate levels, the absence of renal phosphate wasting, and increased renal excretion of calcium. Other characteristic features include normal or suppressed serum parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) concentrations and normal nephrogenous cyclic adenosine monophosphate production.
Dysregulated extra-renal production of calcitriol, the active metabolite of vitamin D, appears to be the underlying defect, although it is unclear whether the lymphoma cells or infiltrating host monocytes and macrophages are the primary source. Applying the pathophysiology of hypercalcemia in sarcoidosis as a model, interferon-y production by lymphocytes stimulating monocyte and macrophage 1 a-hydroxylase activity and enhancing vitamin D activation may be an early initiating event. There is also evidence that other osteolytic factors such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) may act in concert with calcitriol to exacerbate the hypercalcemia. In isolated cases of human T-cell lymphotrophic virus type-1 (HTLV-1 )-related adult T-cell leukemia/lymphoma, where elevated calcitriol levels have been reported, the underlying mechanism is probably stimulation of renal vitamin D activation by PTHrP acting on renal PTH receptors.
Calcitnol ( 1,25-dihydroxyvitamin D,)-mediated hypercalcemia is a distinct pathophysiologic entity within the broad field of malignancy-associated hypercalcemia. At our current level of understanding, it is useful to divide malignancy-associated hypercalcemia into three major categories: humoral hypercalcemia of malignancy usually mediated by PTHrP, local osteolytic hypercalcemia, and hypercalcemia caused by the dysregulated production of calcitriol, the active metabolite of vitamin D (Table 1) . In each category, the underlying pathophysiologic mechanism results in a characteristic clinical picture, although it is possible for more than one mechanism to contribute to the pathogenesis of hypercalcemia in an individual patient.
The most common form of hypercalcemia associated with solid tumors is humoral hypercalcemia of malignancy, mediated by PTHrP,' which acts systemically to causegeneralized increased osteoclastic bone resorption, increased renal resorption of calcium, and renal phosphate wasting ( Table 2 ). These features are often present even in patients with osseous meta~tases.~,, Although PTHrP has been implicated in the hypercalcemia of human T-cell-lymphotrophic virus type-1 (HTLV-1)-related adult T-cell leukemia/ lymphoma (ATLLr and isolated cases of NHL,5,6 most patients with hematologic malignancies complicated by hypercalcemia do not have elevated systemic levels of PTHrP.7-9 Conversely, dysregulated calcitnol production is a very rare occurrence in patients with hypercalcemia associated with solid t~m o r s , '~'~ where suppressed serum concentrations of calcitriol are characteristic.
The second major category of malignancy-associated hypercalcemia is local osteolytic hypercalcemia. The predominant cause of the hypercalcemia in these cases is localized bone resoption by activated osteoclasts in the vicinity of tumor cells metastatic to bone. Although not well characterized, a variety of cytokines and local regulatory factors have been implicated in this type of hypercalcemia (Table 1) . The third major category of hypercalcemia is calcitriolmediated hypercalcemia. This is the most frequent cause of hypercalcemia seen in patients with Hodgkin's disease and NHL,l4,I5 where hypercalcemia has been reported to occur in 5% and 15% of patients, respectively.16 There are no data specifically examining the clinical impact of hypercalcemia in these disorders. However, patients with malignancy-associated hypercalcemia are usually symptomatic, and hypercalcemia adds significantly to their morbidity and mortality.17 Further, hypercalcemia is a poor prognostic feature in a number of hematologic and therapies specifically directed toward preventing osteolysis have shown improved outcomes for patients with both metastatic breast cance?1s22 and multiple myeloma.23s24 Finally, The selection and application of therapy appropriate for calcitriol-mediated hypercalcemia depend on recognition of the disorder and an understanding of the underlying pathophysiologic processes. Characteristic and distinct biochemical profiles are seen in patients within the three categories of malignancy-associated hypercalcemia described, as illustrated in Table 2 . In patients with calcitriol-mediated hypercalcemia there is enhanced osteoclastic bone resoption and excessive gastrointestinal calcium ab~orption.~' The laboratory findings in this clinical syndrome include a normal or suppressed PTH concentration, a normal or slightly elevated serum phosphate, and normal levels of the inactive precursor 25-hydroxyvitamin D, with an elevated calcitriol level, or a calcitriol level that is inadequately suppressed for the degree of hypercalcemia. If measured, the tubular reabsorption of phosphate is normal or increased*' and the nephrogenous cyclic adenosine monophosphate (CAMP) level, an indicator of the activation of renal tubular PTH receptors, is low." These findings contrast those seen in PTHrP-mediated humoral hypercalcemia of malignancy (Table 2) .29
This constellation of findings is an idealized one, and these changes can be modified in an individual patient by the degree of preexisting renal impairment, dietary intake of calcium and fluids, and, most importantly, the interacting influences of other active mediators. There is considerable evidence that other less well-understood cytokines have a role in the causation or modulation of the hypercalcemia mediated by calcitriol. Before these interactions can be fully understood, the underlying physiological regulation of vitamin D production, and its major metabolic actions, must be thoroughly understood.
NORMAL PHYSIOLOGY AND METABOLISM OF CALCITRIOL
A thorough review of the normal physiology of calcitriol has recently been p~blished,~' and only the details directly relevant to the understanding of hypercalcemia in hematologic malignancies will be outlined here.
Exposure of the skin to ultraviolet light (UV) facilitates the conversion of 7-dehydrocholesterol to cholecalciferol (vitamin D,), which then undergoes hepatic hydroxylation to 25-OH-D3. This compound is not known to have biologic activity, and the hepatic 25-hydroxylase is not tightly regulated. Blood levels of 25-OH-D, vary greatly depending on dietary intake and UV exposure. The metabolically active derivatives are produced by a second hydroxylation in the kidney. The major metabolic product is 1 ,25-(OH),-D, (calcitriol). The enzyme involved, I a-hydroxylase, is tightly regulated, and its activity varies inversely with that of the associated 24-hydroxylase, which yields the second significant metabolite: 24,25-(OH),-D,, whose biologic actions are not well characterized. The principal stimuli to enhanced 1 a-hydroxylase activity are hypocalcemia (mediated via parathyroid hormone) and hypophosphatemia (Table 3) . Under normal physiologic circumstances the kidney is the only significant source of circulating calcitriol. Calcitriol itself also directly inhibits the renal la-hydroxylase. Given that PTH stimulates the activity of the renal la-hydroxylase, it is not surprising to find that 1 ,2S-(OH)2-D, levels are often significantly elevated in patients with primary hyperparathyroidPTHrP shares the stimulatory action of PTH on renal la-hydroxyla~e'~,~~ and one of the potential sources of calcitriol in malignancy-associated hypercalcemia is from dysregulated renal production secondary to PTHrP stimulation. However, as discussed below, for poorly understood reasons this is rarely observed.
Calcitriol in plasma is 85% bound to the vitamin D-binding protein, 15% bound to albumin, and less than 1% is in
Synthesis and measurement.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Macrophages are one of the few extra-renal cell types with significant 1 a-hydroxylase activity, and evidence strongly implicates them as the source of calcitriol in the hypercalcemia complicating both sarcoidosis and tuberculosis. Monocytes and macrophages probably have a similar pivotal role in the production of calcitriol in the hypercalcemia complicating lymphomas. Although detailed studies of calcitriol production in hematologic malignancies have not been reported, the cellular mechanisms involved in the hypercalcemia of sarcoidosis provide a potential model. In sarcoidosis and tuberculosis, neither PTH43 nor functional renal tis-S U~~,~' is necessary for the development of an elevated calcitriol level and hypercalcemia. Indeed, macrophages are poorly responsive to PTH in vitro.46 Both sarcoid lymph node homogenate47 and cultured isolated alveolar macrophages from patients with ~a r c o i d o s i s~~~~~ are able to synthesize calcitriol in vitro. Calcitriol synthesis by macrophages is EXTRA-RENAL PRODUCTION OF CALCITRIOL enhanced by interferon-y (IFN-y)50951; however, complex regulatory mechanisms are involved. The 1 a-hydroxylase activity macrophages is inhibited by calcitriol, but to a lesser degree than the renal 1 cu-hydro~ylase,~~ and, normally IFNy secretion by T lymphocytes is also inhibited by calcitri01.'~,'~ These regulatory mechanisms may serve to prevent excessive IFN-y production and continuing extrarenal calcitriol synthesis. However, these inhibitory stimuli can be overcome, as pulmonary T lymphocytes from patients with sarcoidosis spontaneously release IFN-ys4 despite elevated calcitriol levels.
IFN-y alone, although a powerful inhibitor of bone formati~n,~' is insufficient to cause hypercalcemia, as evidenced by the numerous infectious diseases that are associated with prolonged systemic elevations of IFN-y without hyper~alcemia~~ and the absence of hypercalcemia complicating phase-I studies of IFN-y.57*5* Indeed, IFN-y actually inhibits IL-1-mediated bone re~orption.'~ Thus, it is clear that additional factors are involved. IL-10 shares some of the monocyte stimulatory properties of IFN-ym and it has recently been shown that certain phorbol esters can overcome the inhibitory effect of calcitriol on IFN-y production from lymphocytes.61 Both IL-1 and TNF have been reported to increase the expression of IFN-y receptors on monocytes and macrophages,6' potentially enhancing cellular responsiveness to IFN-y . However, despite increasing the number of IL-1 re~eptors,6~ calcitriol has also been reported to inhibit the production of IL-1 by T lymphocytes.64
Thus, there are many complex cytokine interactions that are yet to be fully integrated into a complete understanding of the regulation of calcitriol production by macrophages.
NEOPLASTIC DISORDERS IN WHICH CALCITRIOL IS IMPLICATED AS A CAUSE OF HYPERCALCEMIA
Hodgkin's disease, NHL and HTLV-1 -related ATLL are the major diseases in which calcitriol is involved in the pathogenesis of hypercalcemia. In each disease the incidence, clinical associations, and prognostic implications of hypercalcemia will be described and the evidence implicating the involvement of other mediators discussed. There have also been isolated reports describing elevated calcitriol levels in acute lymphoblastic leukemia (ALL)65 and myelofibrosis. 66 In ALL, although no large series have been reported, hypophosphatemia and lytic bone lesions often accompany hyper~alcemia.~~ These features, and the recent report of a patient with ALL and an elevated PTHrP leve1,6* suggest that factors other than calcitriol are likely to be involved. Similarly, there is no evidence implicating calcitriol in the hypercalcemia associated with acute myeloid leukemia (AML),69 multiple myeloma,14s70 chronic myeloid leukemia (CML),7' chronic lymphocytic le~kemia,~' or Waldenstrom's macr~globulinemia.~~
HODGKIN'S DISEASE
Hodgkin's disease is the disorder in which calcitriol is most consistently implicated as the mediator of hypercalcemia and in which the most extensive clinical studies have been conducted. Hypercalcemia was first reported to comFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From plicate Hodgkin's disease by Plimpton and Gellhom in 1956," and the association with increased vitamin D sensitivity was described one year later by Kabakow et aL7' Since that time more than 60 cases have been described.1c'6*76'02 Only three studies report the incidence of this complication, and these used a variety of methods and definitions of hypercalcemia. Using hospital admission data and the thresholds of 10.8 mg/dL and 10.3 mg/dL for hypercalcemia, respectively, incidences of I .6% ( 1 /6 I ) 76 and 5.4% ( IS/ 276)16 have been reported. Limiting his analysis only to patients with stage IV Hodgkin's disease and using an unspecified threshold, Canellos7' reported a 0.9% (l/109) incidence of hypercalcemia. The incidence of significant hypercalciuria is probably higher. In an autopsy study Moses and Spencer7' found nephrocalcinosis, an indicator of longstanding hypercalciuria, in 8 of 19 patients with lymphoma (including I I with Hodgkin's disease) who had not been known to be hypercalcemic during life.
In 38 patients the actual peak serum calcium levels were reported and the distribution of these values is shown in Fig  1. The peak serum calcium values ranged from 10.9 to 23. I mg/dL (median 14.4 mg/dL), 84% of patients had a peak serum calcium above 12 mg/dL, showing that the hypercalcemia is usually severe and clinically significant. In contrast to the hypercalcemia of sarcoidosis, the angiotensin-converting enzyme level has been normal in the four patients m e a s~r e d . '~* '~*~~~~ From those reports in which details are provided, the ages of the patients were 15 to 83 years (median SO), with I5 of42 (36%) 60 years old or more (in 9 cases no individual data was provided). Forty-one of 51 (80%) were male, and for 29 patients the histologic subtype was described (Table 4 ). In 38 patients the Ann Arbor stage at the time of diagnosis of hypercalcemia was described (Fig   2) . The clinical features and histologic subtypes in these hypercalcemic patients contrast with those reported from large series of patients with Hodgkin's disease, in which the age distribution is bimodal and the majority of cases occur in the 15-to 35-year-old age group.lo4 Of the reported patients with hypercalcemia, only l l of42 (26%) were within Distribution of histologic subtypes from National Cancer Institute sen e~. '~~ t Twenty-nine cases of hypercalcemia complicated by hypercalcemia with histologic subtyping given: see text for references. this age range. The incidence of Hodgkin's disease is greater in males, constituting up to 60% of cases. ' @' This is notably less than the 80% of males among those patients with hypercalcemia. Table 4 shows the distribution of the histologic subtypes of patients with Hodgkin's disease seen at the National Cancer Institute'03 and clearly shows that the nodular-sclerosing subtype is significantly under-represented among those patients with hypercalcemia. As discussed below, many of the patients with hypercalcemia presented with predominantly infradiaphragmatic disease. Some reports have described an older age at diagnosis, a greater proportion of males, and a lower incidence of nodular-sclerosing histology among patients presenting with infradiaphragmatic Hodgkin's disease.10s.'" A second possible explanation for these significant differences is pathologic mis-classification in some instances, or the inclusion of cases of NHL. Indeed, in 1986 a pathologic review of the cases of lymphocyte-depleted Hodgkin's disease seen at the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From abdominal adenopathy was also present in two other patients who were reclassified as having NHL.lo7 It is not possible to clarify this issue in a retrospective literature review.
Contrary to the general belief that hypercalcemia is usually a complication of extensive osseous disease, only 3 of the 23 patients for whom sufficient data are available had radiologic evidence of lytic bone lesions77.97*98 and one had diffuse osteopor~sis.~~ Some patients displayed diffuse enhancement of radiotracer uptake on nuclear bone scanning in the absence of distinct radiologic bone lesion^.'^^^^ As suggested above, the metabolic profile of these patients is not consistent with the humoral hypercalcemia of malignancy mediated by PTHrP. Only 9 of 35 reported patients had a phosphate level below the normal range during the hypercalcemic episode.75,78,82*95 Cyclic AMP levels have consistently been low or norma1.79,82,83,86,95 Normal or suppressed PTH levels have been reported, with normal parathyroid glands documented at autopsy or neck exploraThe lack of any large series of patients administered uniform treatment precludes any meaningful analysis of the prognostic significance of hypercalcemia in Hodgkin's disease. In many of the reported patients independently poor prognostic features were present. Disease was often described as bulky. Twenty-eight of 38 patients (74%) had Ann Arbor stage I11 or IV disease (Fig 2) . Further, 17 of 25 patients (68%) had "B' symptoms. Many of the reported patients did not receive what would currently be considered optimum therapy. However, the presence of hypercalcemia at presentation does not preclude a complete remission to therapy and a long-term disease-free survival with standard therapy."9101
The calcitriol levels of 17 patients, measured while hyperIn only one was the level not elevated." This patient was positive for antibodies to the HIV-1. Although no details are provided, Rosenthal et a179 also refer to an unpublished instance of a hypercalcemic patient with Hodgkin's disease and a normal calcitnol level. The available data show that nearly all patients with hypercalcemia complicating Hodgkin's disease have elevated calcitriol levels, indicating that this mediator is intimately involved in the pathogenesis of this syndrome. Evidence implicating additional mediators in the hypercalcemia of Hodgkin's disease. Two patients are de~cribed'~9'~ for whom it appears calcitriol was the sole factor responsible for the hypercalcemia. These patients were normocalcemic, with normal calcitriol levels, until they were exposed to UV or received vitamin D supplementation.
These maneuvers resulted in hypercalcemia and concurrent elevations of calcitriol levels that normalized after the causative agent was withdrawn.
However, in most instances, the data strongly implicate the action of additional factors. Jacobson et als4 studied the bone-resorbing activity of lymph node homogenate from a patient with hypercalcemia complicating Hodgkin's disease. Significant bone-resorbing activity remained after removal of calcitriol, and bone-resorbing ability did not parallel I ,25-(OH),-D3 concentration in dilution studies. In tion. 14,74,75,85,93, 96 calcemic, have been reported (Fig 1).14,~5,79,82-84.87-~.92.94,95.~0~ reported cases the calcitriol levels range from 1.12 to 5.4 (mean 2.0) times the upper limit of normal (Fig 1) . In studies of oral calcitriol administration to normal volunteers, plasma levels up to twice the upper limit of normal for brief periods did not result in significant Further, in patients with sarcoidosis and hypercalcemia, the levels of calcitriol associated with comparable degrees of hypercalcemia are significantly higher.'"
The identities of these putative additional mediators are uncertain. There is no evidence available to date to implicate PTHrP in Hodgkin's disea~e.'~,~'*'~~ However, IL-I, a cytokine with independent osteolytic activity, has been implicated. IL-1 mRNA is present within Reed-Stemberg cells"' and the IL-1 protein has been shown by immunohistochemistry to be present within both Reed-Stemberg cells' '' and the infiltrating host macrophages.'" Circulating levels of IL-1 are also elevated in a minority of patients with untreated Hodgkin's disease."' As discussed earlier, there is also a possible link between IL-1 and the stimulation of IFN-y-induced macrophage calcitriol production. Any possible correlation between hypercalcemia and IL-1 levels in Hodgkin's disease has not been investigated.
NHL
Hypercalcemia occurs most commonly in aggressive histologic types of NHL. In a recent study from the M.D. Anderson Cancer Center, 9 of 2 19 (4.1 %) newly registered patients with NHL of all grades were hypercalcemic (total calcium 210.8 mg/dL); in 3 patients (1.4%) the calcium level was > 12.0 mg/dL.'I4 The incidence of hypercalcemia in high-and intermediate-grade NHL (according to the International Working F~rmulation''~) may be as high as 30%.'6,''6 This rising incidence with increasing histologic grade correlates with the degree of host macrophage infiltration of lymphomatous tissue, recognized histologically by the "starry sky" appearance, which is limited to the more aggressive histological subtype^."^ In contrast, hypercalcemia is very uncommon in low-grade NHL, only complicating 1% to 2% of cases.I6 Except in ATLL, in which hypercalcemia is a powerful adverse prognostic factor," no data is available concerning the prognostic significance of hypercalcemia in NHL.
An unknown percentage of patients who have NHL without overt hypercalcemia have hypercalciuria?' suggesting the presence of a calciotropic mediator, perhaps inappropriately elevated levels of 1,25-(OH),-D3, even in the absence of hypercalcemia. In these patients with hypercalciuria, the risk of subsequent hypercalcemia may be increased, although this issue has not been systematically investigated.
The literature contains reports of at least 19 instances of elevated serum calcitriol levels associated with hypercalcemia in patients with NHL.'4,79,",'17-'22 Fourteen (74%) of these patients were male, their median age was 58 years (range 4 to 8 1 years), and only one patient9' had low-grade histology, and one an uncommon angiocentric lymphoma.Iz2 The small number of patients and the anecdotal nature of these reports, combined with the broad range of clinical features in NHL, precludes a meaningful comparison of these patients with nonhypercalcemic NHL patients.
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However, a few points are noteworthy. Firstly, although many patients had bulky or advanced-stage disease, none had bone lesions identified clinically or radiographically. This excludes direct tumoral osteolysis as a major contributor to the hypercalcemia. Both B-and T-cell phenotypes have been reported to be associated with elevated calcitriol levels. It is not known if immunophenotype influences the incidence of hypercalcemia. All patients had normal or elevated phosphate levels, in contrast to PTHrP-mediated humoral hypercalcemia of malignan~y.~~ Finally, where measured, levels of urinary cyclic and were normal or suppressed. The lack of elevations of PTH, the absence of high cAMP levels, and the normal to elevated phosphate levels all support an extrarenal origin of the calcitriol in these patients. The probability of an extrarenal source of calcitriol is further strengthened by the presence of severe renal failure in a number of ins t a n c e~,~~, "~ the demonstration of in vitro conversion of 25-OH-D, to 1 ,25-(OH),-D, by excised lymph node homogenate,lZo the prompt decline of calcitriol levels to normal within 24 hours of excision of an isolated splenic lymp h~m a ,~~ and normal PTHrP levels in all cases where measured.I4 A few cases of hypercalcemia in NHL associated with elevated levels of PTHrP have been r e p~r t e d .~,~. '~~ In only three of these patients were calcitriol levels rep~r t e d ,~, '~~ and all were appropriately suppressed. It appears that simultaneous elevations of the levels of both PTHrP and calcitriol do not commonly occur in NHL. Although both PTHrP-and calcitnol-mediated syndromes may occur in patients with NHL, calcitriol-mediated hypercalcemia is the more common mechanism.I4 pTHl4,79,l I7,1?.1,122
HTLV-1 -RELATED ATLL
The understanding of the complex mechanisms of hypercalcemia in HTLV-I-related ATLL is incomplete. However, PTHrP is most strongly implicated as the major mediaAn early report suggested HTLV-1 -transformed lymphocytes possessed significant 1 a-hydroxylase activity,Iz5 although this capability was substantiated in only one of three HTLV-1 -transformed cell lines examined.'26 Most studies have shown suppressed calcitriol levels in the hypercalcemia associated with ATLL.'4,'27,128 However, there are two well-documented instances of elevated calcitriol levels.'L7,'29 In the first caseiL7 PTHrP levels were not available. The second caseIz9 involved concomitant elevations of calcitriol and PTHrP, suggesting the possibility of increased renal 1 a-hydroxylase activity secondary to stimulation by PTHrP.
INTERACTION OF CALClTRlOL WITH OTHER MEDIATORS
There are data clearly showing dysregulated renal production of calcitriol in response to tumor-derived PTHrP, which shares the 1 a-hydroxylase-stimulating capability of PTH. Infusion of synthetic PTHrP( 1-34) or PTHrP( 1-36) produces significantly elevated levels of circulating calcitri01,,~*~~ and dogs with malignant lymphoma and hypercalcemia often exhibit elevations of both PTHrP and calcitri01.l~~ Patients with an elevated PTHrP level would be expected to have increased renal I a-hydroxylase activity and an elevated calcitriol level in the presence of sufficient precursor 25-OH-D,. However, in most patients with solid tumors complicated by humoral hypercalcemia of malignancy calcitriol levels are, with some exception^,'^.'^' depre~sed."J~~ One of the most intriguing questions about the involvement of calcitriol in the hypercalcemia of malignancy is why levels are not consistently elevated in association with high levels of PTHrP.
There is some recent evidence that the phosphaturic and 1 a-hydroxylase-stimulating activities of PTH can be separated using synthetic ana10gues.l~~ However, both the CAMP-generating and the 1 a-hydroxylase-stimulating activities of PTHrP are localized with the PTHrP( 1-34) fragment,33.34 and it is very unlikely that cleavage within this region can separate these a~tivities."~ It is probable that the failure to exhibit elevations of calcitriol in response to PTHrP is caused by inhibition of the renal 1 a-hydro~ylase.'~~ Evidence suggests that when acting systemically, IL-I may have such properties. Although able to mediate osteolytic bone resorption in i~olation"~ and to act synergistically with PTHrP,137 IL-I is also able to downregulate PTH receptorsL3' and to strongly inhibit PTHrP( 1 -34)-induced renal phosphate wasting and calcium resorption without diminishing urinary cAMP e~c r e t i 0 n . I~~ However, it is yet to be shown that IL-1 is able specifically to inhibit renal la-hydroxylase.
In humoral hypercalcemia of malignancy mediated by PTHrP, the elevated serum calcium is one factor contributing to the suppression of calcitriol. After normalization of the serum calcium by bisphosphonate treatment, which does not have any known antitumor activity or effect on PTHrP levels, calcitriol levels have been shown to increase towards normal.'40 The demonstration of IL-1 cosecretion by PTHrP-producing squamous carcinoma cell lines'4L further strengthens the hypothesis that IL-1 is intimately involved in the causation and modulation of the manifestations of PTHrP-mediated hypercalcemia in some solid tumors.
Other substances have similar activities. TNF-a can downregulate PTH receptors,"' inhibiting renal PTHrP-induced cAMP formation.14* Levels of TNF-a adequate to produce such effects have been detected in the serum of hypercalcemic patients with ATLL. 14, Similarly, transforming growth factor-a (TGF-a) can inhibit the PTH-responsiveness of an osteoblast cell line,'" but it is not known if TGF-a similarly inhibits renal PTH-responsiveness or 1 a-hydroxylase activity.
As discussed above, both IL-1 and TNF have potentially stimulatory actions on macrophage calcitriol production, and it is possible that the local paracrine, and systemic humoral actions of these factors may be distinct, or even counteracting. Elevated systemic levels of IL-1, TNF-a, or TGFa may also explain the failure to frequently observe elevated calcitriol levels in HTLV-1-related ATLL where PTHrP is active. Even a patient with disease progressing on treatmentE9 has shown a lowering of the calcium level with the administration of corticosteroids. One case is particularly illustrative.'2' After liver transplantation a child developed a B-cell NHL while receiving immunosuppressive therapy with cyclosporine A and prednisone. Withdrawal of the cyclosporine A did not influence the progression of the lymphoma or the calcium level. In spite ofactive lymphoma the patient remained normocalcemic until prednisone was withdrawn, at which time hypercalcemia first developed. After surgical debulking, subsequent intermittent administration of therapy including pulse steroids maintained normocalcemia until death despite tumor progression.
The minimum effective dose of corticosteroid is uncertain. However, hypercalcemia has recurred while patients gle agent co~~cos~ero~~s~7~76. 79 These reports clearly show a calcium-lowering effect of corticosteroids distinct from any cytotoxic activity. Although corticosteroids may have some effect on osteob l a s t~'~~ and intestinal calcium a b s~r p t i o n , '~~ the illustrated reductions in calcitriol levels that accompany therapy suggest inhibition ofcalcitriol production. Corticosteroids have pleiotropic effects on lymphocytes, including inhibition of the secretion of the potentially important mediators IFN-y. IL-I, and IL-10.'5""'52The 1 n-hydroxylaseactivityofpulmonary alveolar macrophages is also directly inhibited by corticosteroid~,'~' and the addition of leukotriene C4 reverses this inhibition.Is4 It is feasible that both the inhibition of arachidonate metabolism in macrophages, and the inhibition of stimulatory cytokine production by lymphocytes is responsible for reducing calcitriol levels and improving hypercalcemia in patients with lymphoma.
For patients with sarcoidosis who are intolerant ofcorticosteroids, chloroquine has been shown to reduce calcitriol levels and alleviate hypercal~emia.'~"'~~ This effect may be mediated by inhibition of macrophage IL-l production or by a reduced responsiveness to stimulatory cytokines.'" Ketoconazole has also been shown to reduce calcitriol levels in normal men'" and in patients with primary hyperparathyroidism.lS9 Whether these agents have similar efficacy in calcitriol-mediated hypercalcemia complicating hematologic malignancies is unknown.
OTHER THERAPEUTIC MODALITIES EFFECTIVE IN CALCITRIOL-MEDIATED HYPERCALCEMIA
Unfortunately, serum calcitriol levels are not likely to be readily available when decisions on the management of hypercalcemia need to be made. Although calcitriol is implicated in all well-documented cases of hypercalcemia in immunocompetent patients with Hodgkin's disease, perhaps only 30% of hypercalcemic patients with NHL will have calcitriol as the major m e d i a t~r . '~ Thus, it may not be prudent to limit therapy specifically to calcitriol mediated effects if calcitriol levels are not known. Therapy should also address other possible sources of elevated serum calcium. Thus, there are four main targets for therapeutic intervention available (Table 5) ; the inhibition of calcium mobilization from bone, the reduction of calcium absorption from the intestine, the enhancement of renal calcium excretion, 
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and interference with calcitriol production or action. As discussed above, the most effective inhibitors of calcitriol production are the corticosteroids.
Many agents are available that either stabilize bone to the action of osteoclastic resorption, or inhibit osteoclast function. These include calcitonin, mithramycin, gallium nitrate and the bisphosphonate class of drugs. These agents are the mainstay of the therapy of humoral hypercalcemia of malignancy'60,'6' and the bisphosphonates have also shown activity in calcitriol-mediated hypercalcemia.80.118-'20 Pamidronate is the most effective of the currently available agents and should be a component of the therapy of calcitriol-mediated hypercalcemia, optimally in combination with corticosteroids and specific cytotoxic agents.
In contrast to the humoral hypercalcemia of solid tumors, intestinal calcium absorption is enhanced in calcitriol-mediated hypercalcemia.'" Intestinal calcium absorption can be reduced by the application of a low-calcium diet, or the use of calcium binding resins. As discussed above, a part of the activity ofglucocorticoids may also be to reduce calcium a b~o r p t i o n . '~~ However, severe hypercalcemia associated with elevated calcitriol levels can develop while patients are taking nothing by mouth,79 so additional measures should always be implemented.
Calcitriol does not promote renal tubular calcium resorption, unlike PTH-like factors. However, hypovolemia and renal impairment are common in calcitriol-mediated hypercalcemia, as in any form of hypercalcemia. Thus, volume replacement, preferentially with saline, to ensure restoration of the intravascular volume and a good urine output, is an important fundamental component of t herapy. ' @' VL6' A large volume diuresis induced by loop diuretics is difficult to safely implement and is not of major additional therapeutic benefit.
In most cases calcitriol production is not limited by 25-OH-D, supply, However, some patients have manifested hypercalcemia only following significant sun e x p o s~r e ,~~.~~ presumably secondary to enhanced production of 25-OH-D,. It would be prudent to advise these patients to avoid excessive UV exposure and dietary vitamin D supplements until the hypercalcemia is controlled. In some geographic areas this precaution may be adequate to prevent hypercalcemia.
UNANSWERED QUESTIONS
The data reviewed clearly show that calcitriol is implicated in nearly all instances of hypercalcemia complicating Hodgkin's disease and perhaps 30% to 40% of cases of hypercalcemia in NHL. It is probable, but not definitively proven, that activated infiltrating nonmalignant host macrophages are the cells responsible. Currently, the most effective treatment to inhibit calcitriol production is the use of corticosteroids. These agents have pleitropic effects and their critical site of action remains uncertain. Before it will be possible to more precisely and effectively treat these disorders it will be necessary to more accurately define the host-tumor interactions that initiate and sustain this dysregulated calcitriol production. It remains entirely unknown how the elevated calcitriol levels, and the interactions that produce them, influence the growth, differentiation, and progression of these tumors.
Finally, the question of why renal calcitriol production and serum levels are not routinely elevated in response to PTHrP remains unanswered. Clarification of this issue will increase our understanding of the pathophysiology of both the hypercalcemia of ATLL and the broad field of humoral hypercalcemia of malignancy associated with solid tumors.
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